{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Muscle-+Invasive+Bladder+Cancer&page=2", "query": { "condition": "Non-Muscle- Invasive Bladder Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Muscle-+Invasive+Bladder+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T07:11:42.764Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06510374", "title": "Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intermediate Risk Non-Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "Nadofaragene Firadenovec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 454, "start_date": "2024-10-01", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 50, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06510374" }, { "nct_id": "NCT05375903", "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-muscle Invasive Bladder Cancer", "NMIBC", "Carcinoma in Situ of Bladder", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent" ], "interventions": [ { "name": "UGN-301", "type": "DRUG" }, { "name": "UGN-201", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2022-06-01", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375903" }, { "nct_id": "NCT05951179", "title": "Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "TARA-002", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Protara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2023-09-15", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 40, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 34 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Queen Creek", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05951179" }, { "nct_id": "NCT03498196", "title": "A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Metastatic Bladder Cancer", "Invasive Bladder Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-12-14", "completion_date": "2019-12-09", "has_results": true, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03498196" }, { "nct_id": "NCT06810141", "title": "ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "NMIBC" ], "interventions": [ { "name": "rMBCG", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 66, "location_summary": "Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06810141" }, { "nct_id": "NCT03081858", "title": "Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer Cell Transitional", "Non-Muscle Invasive Bladder Cancer", "Bladder Cancer", "Urinary Bladder", "Transitional Cell Carcinoma of the Bladder", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Urogenital Neoplasms", "Urinary Bladder Diseases", "Urologic Diseases" ], "interventions": [ { "name": "TSD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lipac Oncology LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2018-05-17", "completion_date": "2021-08-05", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 5, "location_summary": "Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hanover", "state": "Maryland" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03081858" }, { "nct_id": "NCT04690699", "title": "LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Bladder Cancer", "Non-muscle-invasive Bladder Cancer" ], "interventions": [ { "name": "Lerapolturev", "type": "BIOLOGICAL" }, { "name": "5% DDM", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Istari Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-08-01", "completion_date": "2024-06-12", "has_results": true, "last_update_posted_date": "2024-10-24", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 1, "location_summary": "Myrtle Beach, South Carolina", "locations": [ { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04690699" }, { "nct_id": "NCT00445601", "title": "S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 406, "start_date": "2007-09", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 70, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 44 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445601" }, { "nct_id": "NCT04871529", "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall", "Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-08-10", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2024-12-30", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 92, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT04871529" }, { "nct_id": "NCT05508568", "title": "A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "ADXBLADDER", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Arquer Diagnostics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 650, "start_date": "2021-07-01", "completion_date": "2023-04", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-06-26T07:11:42.764Z", "location_count": 13, "location_summary": "Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Troy", "state": "Michigan" }, { "city": "Mount Laurel", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05508568" } ] }